Synthetic nanoparticles for systemic immunity modulation in cancer therapy
Advanced PLGA nanoparticles with CD40 and TLR9 agonists enhance immune activation in cancer treatments by repolarizing macrophages and priming dendritic cells, aiming to improve tumor microenvironment modulation and systemic immunity.
Overview
The innovative use of PLGA nanoparticles, densely coated with CD40 agonist antibodies and TLR9 agonists, presents a promising approach in cancer immunotherapy. These nanoparticles are designed to repolarize tumor-associated macrophages and prime dendritic cells, crucial for systemic immune response. By modulating the tumor microenvironment, this technology aims to enhance the efficacy of existing cancer treatments, particularly in challenging 'cold' tumors.
Technical specifications
- PLGA nanoparticles: High-density surface display of CD40 agonist antibodies
- Synergistic modulation: TLR9 agonists co-administered to enhance immune activation
- Activation markers: Nanoparticles shown to significantly increase CD86, MHC-II, and CD40 expression in vitro
- Controlled administration: Use of nano-/micro-carriers with synthetic DNA scaffolds for precise loading and targeted delivery
Technology readiness level
The technology is currently at TRL 3, with ongoing validation efforts including in vitro and in vivo studies to optimize formulations and assess their impact on the tumor microenvironment. Future research will focus on advanced tumor models to further demonstrate efficacy and potential in clinical applications.
About Drexel University
Drexel University is a comprehensive private research university in Philadelphia, recognized for an urban, industry‑embedded model anchored by a longstanding cooperative education program. Year‑round co‑ops create a ready talent pipeline and align sponsored research with real‑world needs. The campus sits within an innovation district with co‑located labs and incubators, enabling companies to collaborate on prototyping with faculty. Through the university’s medical college and clinical partners, industry teams can access clinical expertise and translational pathways. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD. A dedicated technology transfer office manages IP, licensing, corporate research agreements, and startup formation.
Inquire about this partnering listing
Industry applications
delivered to your inbox.